Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rachel Schiff

Showing results (121-130 of 199) with videos related to

Pageof 20
Sort By:
Clinical Breast Cancer|August 8, 2015
Basal Protein Expression Is Associated With Worse Outcome and Trastuzamab Resistance in HER2+ Invasive Breast CancerAlice Chung, Michael Choi, Bing-chen Han, et al.
Nature Communications|April 22, 2020
Author Correction: Temporal dynamic reorganization of 3D chromatin architecture in hormone-induced breast cancer and endocrine resistanceYufan Zhou, Diana L Gerrard, Junbai Wang, et al.
Cancers|May 28, 2022
Endocrine Therapy-Resistant Breast Cancer Cells Are More Sensitive to Ceramide Kinase Inhibition and Elevated Ceramide Levels Than Therapy-Sensitive Breast Cancer CellsPurab Pal, Alec Millner, Svetlana E Semina, et al.
NPJ Breast Cancer|December 5, 2018
Cyclin E1 and Rb modulation as common events at time of resistance to palbociclib in hormone receptor-positive breast cancerCristina Guarducci, Martina Bonechi, Matteo Benelli, et al.
Nature Communications|April 5, 2019
Temporal dynamic reorganization of 3D chromatin architecture in hormone-induced breast cancer and endocrine resistanceYufan Zhou, Diana L Gerrard, Junbai Wang, et al.
Biochimica Et Biophysica Acta. Gene Regulatory Mechanisms|September 21, 2020
The 3D genomic landscape of differential response to EGFR/HER2 inhibition in endocrine-resistant breast cancer cellsYini Yang, Lavanya Choppavarapu, Kun Fang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 8, 2011
Cytoplasmic estrogen receptor in breast cancerAllison W Welsh, Donald R Lannin, Gregory S Young, et al.
Cancer Cell|June 15, 2013
PDEF promotes luminal differentiation and acts as a survival factor for ER-positive breast cancer cellsGilles Buchwalter, Michele M Hickey, Anne Cromer, et al.
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|June 10, 2021
A novel role of ADGRF1 (GPR110) in promoting cellular quiescence and chemoresistance in human epidermal growth factor receptor 2-positive breast cancerNoor Mazin Abdulkareem, Raksha Bhat, Lanfang Qin, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 12, 2011
Gefitinib or placebo in combination with tamoxifen in patients with hormone receptor-positive metastatic breast cancer: a randomized phase II studyC Kent Osborne, Patrick Neven, Luc Y Dirix, et al.
Pageof 20

Showing results (121-130 of 199) with videos related to

Sort By:
Pageof 20
Clinical Breast Cancer|August 8, 2015
Basal Protein Expression Is Associated With Worse Outcome and Trastuzamab Resistance in HER2+ Invasive Breast CancerAlice Chung, Michael Choi, Bing-chen Han, et al.
Nature Communications|April 22, 2020
Author Correction: Temporal dynamic reorganization of 3D chromatin architecture in hormone-induced breast cancer and endocrine resistanceYufan Zhou, Diana L Gerrard, Junbai Wang, et al.
Cancers|May 28, 2022
Endocrine Therapy-Resistant Breast Cancer Cells Are More Sensitive to Ceramide Kinase Inhibition and Elevated Ceramide Levels Than Therapy-Sensitive Breast Cancer CellsPurab Pal, Alec Millner, Svetlana E Semina, et al.
NPJ Breast Cancer|December 5, 2018
Cyclin E1 and Rb modulation as common events at time of resistance to palbociclib in hormone receptor-positive breast cancerCristina Guarducci, Martina Bonechi, Matteo Benelli, et al.
Nature Communications|April 5, 2019
Temporal dynamic reorganization of 3D chromatin architecture in hormone-induced breast cancer and endocrine resistanceYufan Zhou, Diana L Gerrard, Junbai Wang, et al.
Biochimica Et Biophysica Acta. Gene Regulatory Mechanisms|September 21, 2020
The 3D genomic landscape of differential response to EGFR/HER2 inhibition in endocrine-resistant breast cancer cellsYini Yang, Lavanya Choppavarapu, Kun Fang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 8, 2011
Cytoplasmic estrogen receptor in breast cancerAllison W Welsh, Donald R Lannin, Gregory S Young, et al.
Cancer Cell|June 15, 2013
PDEF promotes luminal differentiation and acts as a survival factor for ER-positive breast cancer cellsGilles Buchwalter, Michele M Hickey, Anne Cromer, et al.
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|June 10, 2021
A novel role of ADGRF1 (GPR110) in promoting cellular quiescence and chemoresistance in human epidermal growth factor receptor 2-positive breast cancerNoor Mazin Abdulkareem, Raksha Bhat, Lanfang Qin, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 12, 2011
Gefitinib or placebo in combination with tamoxifen in patients with hormone receptor-positive metastatic breast cancer: a randomized phase II studyC Kent Osborne, Patrick Neven, Luc Y Dirix, et al.
Pageof 20